Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057286 | 0.81 | HTT (0.50) | LMNASMN1; SMN2L3MBTL1HTTKEAP1 | |
| SCHEMBL1284434 | 0.81 | SIRT5 (0.50) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL5149463 | 0.80 | TGM2 (0.50) | LMNASMN1; SMN2L3MBTL1HTTKEAP1 | |
| SCHEMBL30683113 | 0.78 | PIN1 (0.59) | LMNAL3MBTL1HTTPIN1 | |
| SCHEMBL12423709 | 0.78 | PIN1 (0.59) | LMNAL3MBTL1HTTPIN1 | |
| SCHEMBL30829589 | 0.76 | LMNA (0.65) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL3811564 | 0.74 | L3MBTL1 (0.80) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL34465942 | 0.73 | PLAU (0.53) | LMNASMN1; SMN2L3MBTL1HTTKEAP1 | |
| SCHEMBL17536575 | 0.73 | L3MBTL1 (0.59) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL4549856 | 0.73 | ALDH1A1 (0.39) | LMNASMN1; SMN2L3MBTL1HTTKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327356-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4320103-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217118-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327356-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | NRAS, KRAS, BRAF | LMNA 4069/4885SMN1; SMN2 4493/4885L3MBTL1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.